Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07237022

The Role of TRP Channels in DPN

The study aims to characterize the vascular response upon topical application of cinnamaldehyde, allyl isothiocyanate and capsaicin on feet skin in healthy volunteers. The vascular response will be characterized in terms of response over time, dose-response, inter-foot and inter-period reproducibility.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Center for Clinical Pharmacology

Leuven, 3000, Belgium

Location status: Recruiting

Location contact

Heleen Marynissen

CONTACT

[email protected]

+3216347014

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is a white male or female ≥18 and ≤45 years of age
  • Subject is a non-smoker for at least 6 months prior to the start of the study
  • Subject has a body mass index (BMI) between 18-30 kg/m²
  • Subject is judged to be in good general health on the basis of medical history, physical examination and vital signs
  • Subject understands the procedures and agrees to participate in the study by giving written informed consent.

Exclusion criteria

  • Subject has a history of any illness or disorder which, in the investigator's opinion, might confound the results of the study
  • Subject has a history of significant severe (drug) allergies
  • Subject is a female who is pregnant, breast-feeding or intends to become pregnant, or is of child-bearing potential and is not using an adequate contraceptive method
  • Subject uses any prescription or non-prescription drugs on a regular basis which, in the investigator's opinion, might confound the results of the study
  • Subject currently uses lotions, oils, depilatory preparations, makeup, or other topical treatments on the feet on a regular basis which cannot be discontinued for the duration of the study
  • Subject has eczema, scleroderma, psoriasis, dermatitis or keloids, tumors, ulcers, burns, skin flaps or grafts on the volar surface of the forearm or the dorsum of the feet, or any other skin abnormality that, in the opinion of the investigator, may interfere with the study assessments
  • Subject has excessive hair growth on the volar surface of the forearms or the dorsum of the feet
  • Subject has any of the following vital sign measurements at screening after at least 10 minutes of supine rest: Heart Rate <40 or >100 beats/min, Diastolic Blood Pressure <50 or >90 mmHg, Systolic Blood Pressure <90 or >140 mmHg
  • Subject is unable to refrain from drinking caffeinated beverages (e.g. coffee, tea, cola, …) 24 hours prior to each study visit. Subject is unable to limit their intake of caffeinated beverages to ≤4 cups a day throughout the study
  • Subject is unable to refrain from drinking alcohol 24 hours prior to each study visit, is currently a regular user of illegal drugs, or has a history of substance abuse (including alcohol)
  • Subject is currently participating or has been involved in testing an investigational drug in another clinical study within the last 4 weeks
  • Subject is in a situation or has a condition which, in the opinion of the investigator, may interfere with safe and optimal participation in the study

Treatment and study plan

Cinnamaldehyde

Other

A 10% and 30% cinnamaldehyde solution is topically applied on foot skin.

Allyl isothiocyanate (AITC)

Other

A 15% and up to 30% AITC solution is topically applied on foot skin.

Capsaicin

Other

A 1.5% and 5% capsaicin solution is topically applied on foot skin.

Primary outcomes

  1. Dermal Blood Flow response (PU)

    Time frame: Up until 60 minutes after cinnamaldehyde and AITC application; and up until 90 minutes after capsaicin application.

    The DBF response prior to and at each point in time after topical application of cinnamaldehyde, AITC and capsaicin on the foot, assessed with LSCI, within the area of application, expressed in arbitrary perfusion units (PU).

  2. Flare area (mm²)

    Time frame: Up until 60 minutes after cinnamaldehyde and AITC application; and up until 90 minutes after capsaicin application.

    The flare area of the DBF response prior to and at each point in time after topical application of cinnamaldehyde, AITC and capsaicin on the feet, assessed with LSCI.

Secondary outcomes

  1. Numeric Rating Scale (NRS) pain score

    Time frame: Up until 60 minutes after cinnamaldehyde and AITC application; and up until 90 minutes after capsaicin application.

    The Numeric Rating Scale (NRS)-11 pain score at each point in time after topical application of cinnamaldehyde, AITC and capsaicin on the feet.

Study contacts

Contact information is provided by the study sponsor or research team.

Heleen Marynissen

CONTACT

[email protected]

+3216347014

Sponsors and collaborators

Lead sponsor

Universitaire Ziekenhuizen KU Leuven

Other

Registry information

Official study title

The Role of Transient Receptor Potential Channels in Diabetic Peripheral Neuropathy

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Nov 19, 2025
Registry last updated
Nov 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.